Prognostic significance of tyrosinase expression in sentinel lymph node biopsy for ultra-thin, thin, and thick melanomas

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 10, 2012, Pages 1367-1376

  Gradilone, A ^a   Gazzaniga, P ^a   Ribuffo, D ^b   Bottoni, U ^c   Frati, L ^a   Agliano A M ^a   Sorvillo, V ^a   Piperno, A ^a   Scuderi, N ^a   Cigna, E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Melanoma; RT PCR; Sentinel lymph node; Thin melanoma; Tyrosinase

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; DEATH; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; ENZYMOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY;

EID: 84871853789     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. TASDEMIR C, TURKMEN SAMDANCI E, DOGAN M, ELMALI C, YASAR SARGIN S. Primer malignant melanoma of kidney: a case report. Eur Rev Med Pharmacol Sci 2011; 15: 971-972.
2. GRECO M, VITAGLIANO T, FIORILLO MA, ATZENI M, CORONA A, RIBUFFO D. Rare malignant tumors of the scalp: a report of four cases, their treatment and a review of the literature. Eur Rev Med Pharmacol Sci 2010; 14: 993-997.
3. JEMAL A, SIEGEL R, WARD E. Cancer statistics. CA Cancer J Clin 2006; 56: 106-130.
4. BARZILAI DA, COOPER KD, NEUHAUSER D, RIMM AA, COOPER GS. Geographic and patient variation in receipt of surveillance procedures after local excision of cutaneous melanoma. J Invest Dermatol 2004; 122: 246-255. (Pubitemid 38281041)
5. BALCH CM, BUZAID AC, SOONG SJ, ATKINS MB, CASCINELLI N, COIT DG, FLEMING ID, GERSHENWALD JE, HOUGHTON A JR, KIRKWOOD JM, MC MASTERS KM, MORTON DL, REINTGEN DS, ROSSI MI, SOBER A, THOMPSON JA, THOMPSON JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648. (Pubitemid 32786276)
6. BALCH CM, GERSHENWALD JE, SOONG SJ, THOMPSON JF, ATKINS MB, BYRD DR, BUZAID AC, COCHRAN AJ, COIT DG, DING S, EGGERMONT AM, FLAHERTY KT, GIMOTTY PA, KIRKWOOD JM, MCMASTERS KM, MIHM MC JR, MORTON DL, ROSSI MI, SOBER AJ, SONDAK VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
7. BALCH CM, SOONG SJ, GERSHENWALD JE, THOMPSON JF, REINTGEN DS, CASCINELLI N, URIST M, MCMASTERS KM, ROSSI MI, KIRKWOOD JM, ATKINS MB, THOMPSON JA, COIT DG, BYRD D, DWSMOND R, ZHANG Y, LIU PY, LYMAN GH, MORABITO A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
8. KALADY MF, WHITE RR, JOHNSON JL. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238: 528-535.
9. HALPERN AC, MARGHOOB AA. Thin melanoma: still "excellent prognosis" disease? J Clin Oncol 2004; 22: 3651-3653.
10. MORTON DL, WEN DR, WONG JH, ECONOMOU JS, CAGLE LA, STORM FK, FOSHAG LJ, COCHRAN AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
11. CASCINELLI N, BELLI F, SANTINAMI M, FAIT V, TESTORI A, RUKA W, CAVALIERE R, MOZZILLO N, ROSSI CR, MACKIE RM, NIEWEG O, PACE M, KIROV K. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7: 469-474. (Pubitemid 30439307)
12. AGNESE DM, ABDESSALAM SF, BURAK WE JR. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003; 134: 542-547.
13. WANG X, HELLER R, VANVOORHIS N, CRUSE CW, GLASS F, FENSKE N, BERMAN C, LEO-MESSINA J, RAPPAPORT D, WELLS K. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patient with malignant melanoma. Ann Surg 1994; 220: 768-774. (Pubitemid 24376375)
14. SMITH B, SELBY P, SOUTHGATE J, PITTMAN K, BRADLEY C, BLAIR GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
15. MELLADO B, COLOMER D, CASTEL T, MUÑOZ M, CARBALLO E, GALÁN M, MASCARÓ JM, VIVES-CORRONS JL, GRAU JJ, ESTAPÉ J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996; 14: 2091-2097. (Pubitemid 26230111)
16. HERSHKO DD, ROBB BW, LOWY AM, AHMAD SA, RAMADAS GH, SOLDANO DA, SUSSMAN JJ. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 2006; 93: 279-285.
17. GRADILONE A, RIBUFFO D, SILVESTRI I, CIGNA E, GAZZANIGA P, NOFRONI I, ZAMOLO G, FRATI L, SCUDERI N, AGLIAǸ AM. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance. Ann Surg Oncol 2004; 11: 983-987. (Pubitemid 40486664)
18. SCHOONJANS F, ZALATA A, DEPUYDT CE, COMHAIRE FH. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 1995; 48: 257-262. (Pubitemid 26020881)
19. WARYCHA MA, ZAKRZEWSKI J, NI Q, SHAPIRO RL, BERMAN RS, PAVLICK AC, POLSKY D, MAZUMDAR M, OSMAN I. Meta-analysis of sentinel lymph node positivity in thin melanoma (≤ 1 mm). Cancer 2009; 115: 869-879.
20. STITZENBERG KB, GROBEN PA, STERN SL, THOMAS NE, HENSING TA, SANSBURY LB, OLLILA DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol 2004; 11: 900-906. (Pubitemid 40486675)
21. KOSKIVUO I, SUOMINEN E, NIINIKOSKI J, TALVE L. Sentinel node metastasectomy in thin
22. SCOGGINS CR, ROSS MI, REINTGEN DS, NOYES RD, GOYDOS JS, BEITSCH PD, URIST MM, ARIYAN S, DAVIDSON BS, SUSSMAN JJ, EDWARDS MJ, MARTIN RC, LEWIS AM, STROMBERG AJ, CONRAD AJ, HAGENDOORN L, ALBRECHT J, MCMASTERS KM. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24: 2849-2857. (Pubitemid 46630585)
23. MOCELLIN S, HOON DS, PILATI P, ROSSI CR, NITTI D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25: 1588-1595. (Pubitemid 46733087)
24. GRADILONE A, GAZZANIGA P, RIBUFFO D, SCARPA S, CIGNA E, VASATURO F, BOTTONI U, INNOCENZI D, CALVIERI S, SCUDERI N, FRATI L, AGLIAǸ AM. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003; 21: 306-312. (Pubitemid 46606160)
25. RIBUFFO D, GRADILONE A, VONELLA M, CHIUMMARIELLO S, CIGNA E, HALIASSOS N, MASSA R, SILVESTRI I, CALVIERI S, FRATI L, AGLIAǸ AM, SCUDERI N. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol 2003; 10: 396-402. (Pubitemid 40486937)
26. RA JH, MCMASTERS KM, SPITZ FR. Should all melanoma patients undergo sentinel lymph node biopsy? Curr Opin Oncol 2006; 18: 185-188. (Pubitemid 43740440)
27. RANIERI JM, WAGNER JD, WENCK S, JOHNSON CS, COLEMAN JJ 3RD. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006; 13: 927-932.
28. PULEO CA, MESSINA JL, RIKER AI, GLASS LF, NELSON C, CRUSE CW, JOHNSON TM, SONDAK VK. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005; 12: 230-235. (Pubitemid 41552314)
29. WONG SL, MORTON DL, THOMPSON JF. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006; 13: 809-816. (Pubitemid 43727365)
30. ELIAS EG, ZAPAS JL, MCCARRON BEAM SL, HASSKAMP JH, CULPEPPER WJ. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/-autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm 2008; 23: 285-291. (Pubitemid 351931453)
31. LENS M, FERRUCCI PF, TESTORI A. Anti-CTLA4 Monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings. Recent Pat Anticancer Drug Discov 2008; 3: 105-113.
32. BALCH CM, SOONG SJ, BARTOLUCCI AA, URIST MM, KARAKOUSIS CP, SMITH TJ, TEMPLE WJ, ROSS MI, JEWELL WR, MIHM MC, BARNHILL RL, WANEBO HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-263.
33. CECCHI R, BURALLI L, INNOCENTI S, DE GAUDIO C. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007; 34: 512-515. (Pubitemid 47228525)
34. WONG SL, BRADY MS, BUSAM KJ, COIT DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13: 302-309. (Pubitemid 43255912)
35. SHAW HM, MCCARTHY WH, MCCARTHY SW, MILTON GW. Thin malignant melanomas and recurrence potential. Arch Surg 1987; 122: 1147-1150. (Pubitemid 18025615)
36. ORLOW SJ, HEARING VJ, SAKAI C, URABE K, ZHOU BK, SILVERS WK, MINTZ B. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 1995; 92: 10152-10156.